News

GSK plc announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Benlysta (belimumab), a B-cell inhibiting monoclonal antibody, for the…
Read More...

Cybin Inc., a biopharmaceutical company focused on progressing Psychedelics to Therapeutics is pleased to announce that it has received approval from an independent ethics committee in…
Read More...

Daewoong Pharmaceutical(CEO Seng-ho Jeon and Chang-jae Lee) has secured an exclusive licensing agreement with CS Pharmaceuticals ("CSP"), a UK based multinational company focused on the…
Read More...

uniQure N.V. and Apic Bio announced that they have entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), a…
Read More...

Ascletis Pharma Inc. announces that the U.S. Food and Drug Administration ("FDA") has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus (RSV)…
Read More...

Sun Pharmaceutical announced that it has acquired three brands viz. Disperzyme (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD (Trypsin BP 48 mg,…
Read More...

Hillstream BioPharma, Inc., a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell…
Read More...

Charles River Laboratories International, Inc. announced that it has acquired SAMDI Tech, Inc, a leading provider of high-quality, label-free high-throughput screening (HTS) solutions…
Read More...

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
Read More...

Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of…
Read More...

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union (EU) to treat eosinophilic esophagitis (EoE) in adults and…
Read More...

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced that the U.S. Food and Drug Administration…
Read More...

Rewind Therapeutics announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors…
Read More...

Evotec SE announced that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies…
Read More...

Roche and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. The XBB.1.5 variant is…
Read More...

BioArctic AB's (publ) partner Eisai announced that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational…
Read More...

CytomX Therapeutics, Inc. announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas. The clinical candidate is the first Probody TCB molecule to…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential…
Read More...

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic…
Read More...

Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, announced that it has raised additional funding, with Sunstone Life Science…
Read More...